Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys

Nuclear Medicine and Biology

Volumn 31, Issue 2, 2004, Pages 231-239

  Kopecky, Martin ^a   Semecky, Vladimir ^a   Trejtnar, Frantisek ^a   Laznicek, Milan ^a   Laznickova, Alice ^a   Nachtigal, Petr ^a   Decristoforo, Clemens ^b   Mather, Stephen J ^c   MäcKe, Helmut R ^d  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

HYNIC Tyr3 octreotide; 99mTc EDDA; 99mTc octreotide; Microautoradiography; Rat kidney perfusion; Renal handling

Indexed keywords

ACETIC ACID DERIVATIVE; ETHYLENE DIAMINE N,N' DIACETIC ACID TC 99M; OCTREOTIDE; OCTREOTIDE TC 99M; OCTREOTIDE[HYDRAZINONICOTINYL 3 TYROSINE]; RADIOISOTOPE; SOMATOSTATIN; UNCLASSIFIED DRUG; 99MTC OCTREOTIDE; 99MTC-OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M EDDA HYNIC TYR(3) OCTREOTIDE; TECHNETIUM 99M EDDA-HYNIC-TYR(3)-OCTREOTIDE; TECHNETIUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BIOACCUMULATION; CONTROLLED STUDY; DRUG UPTAKE; KIDNEY; KIDNEY CELL; KIDNEY CLEARANCE; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY MEDULLA; KIDNEY PERFUSION; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; RAT; ANIMAL; COMPARATIVE STUDY; EVALUATION; KIDNEY SCINTISCANNING; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; RADIOISOTOPE RENOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 1542345723     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.06.001     Document Type: Article

References (34)

1. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 28:2001;836-846.
2. Breeman W.A.P., de Jong M., Kwekkeboom D.J., Valkema R., Bakker W.H., Kooij P.P.M., Visser T.J., Krenning E.P. Somatostatin receptor-mediated imaging and therapy basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 28:2001;1421-1429.
3. Reubi J.C., Schär J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., Mäcke H.R. Affinity profiles for human somatostatin receptor subtypes sst1 -sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 27:2000;273-282.
4. 3-octreotide. J Nucl Med. 33:1992;652-658.
5. Krenning E.P., de Jong M., Kooij P.P.M., Breeman W.A.P., Bakker W.H., de Herder W.W., van Eijck C.H., Kwekkeboom D.J., Jamar F., Pauwels S., Valkema R. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 10:(Suppl 2):1999;23-29.
6. 99mTc in vitro stability, in vivo validity and comparison with 111In-DTPA-octreotide. Pept Res. 9:1996;144-150.
7. Maina T., Stolz B., Albert R., Bruns C., Koch P., Maecke H.R. Synthesis and biological evaluation of a new somatostatin analogue (SDZ 219-318) labelled with technetium-99m. Eur J Nucl Med. 21:1994;437-444.
8. 99mTc[N4- (D)PHE1]-octreotide, a new octreotide derivative with high affinity for somatostatin receptors. Nicolini M., Banoli G., Mazzi U. Technetium and rhenium in chemistry and nuclear medicine 4. 1995;395-400 SG Editorali, Padova.
9. 111In-labelled octreotide derivatives. Eur J Nucl Med. 27:2000;1318-1325.
10. Maecke H.R., Behe M. New octreotide derivatives labelled with technetium-99m. J Nucl Med. 37:(Suppl):1996;29.
11. Behr T.M., Goldenberg D.M., Becker W. Reducing the renal uptake of radiolabelled antibody fragments and peptides for diagnosis and therapy present status, future prospects and limitations. Eur J Nucl Med. 25:1998;201-212.
12. Duncan J.R., Behr T.M., De Nardo S. Intracellular fate of radiometals. J Nucl Med. 38:1997;659-671.
13. Behr T.M., Sharkey R.M., Juweid M.E., Blumenthal R.D., Dunn R.M., Griffiths G.L., Bair H.J., Wolf F.G., Becker W.S., Goldenberg D.M. Reduction of the renal uptake of radiolabelled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 55:1995;3825-3834.
14. Behr T.M., Becker W.S., Sharkey R.M., Juweid M.E., Dunn R.M., Bair H.J., Wolf F.G., Goldenberg D.M. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med. 37:1996;829-833.
15. de Jong M., Rolleman E.J., Bernard B.F., Visser T.J., Bakker W.H., Breeman W.A.P., Krenning E.P. Inhibition of the renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 37:1996;1388-1392.
16. 99mTc-labeled lanreotide for detection of somatostatin receptor-positive tumors. Sci Pharm. 69:2001;322.
17. 99mtechnetium labelled peptides. J Nucl Med. 41:2000;177-182.
18. Heyrovsky A. A new method for the determination of inulin in plasma, and urine. Clin Chim Acta. 1:1956;470-474.
19. Laznicek M., Senius K.E.O. Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur J Clin Pharmacol. 30:1986;591-596.
20. Durie B.G., Salmon S.E. High-speed scintillation autoradiography. Science. 190:1975;1093-1095.
21. Reubi J.C., Horisberger U., Studer U.E., Waser B., Laissue J.A. Human kidney as target for somatostatin high affinity receptors in tubules and vasa recta. Clin Endocrinol Metab. 77:1993;1323-1328.
22. Boerman O.C., Oyen W.J.G., Corstens F.H.M. Between the Scylla and Charybdis of peptide radionuclide therapy hitting the tumor and saving the kidney. Eur J Nucl Med. 28:2001;1447-1449.
23. 1-octreotide in rats. Eur J Drug Metab Pharmacokin. 27:2002;37-43.
24. Decristoforo C., Mather S.J. 99m-technetium-labeled peptide-HYNIC conjugates effects of lipophilicity and stability on biodistribution. Nucl Med Biol. 26:1999;389-396.
25. 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 27:2001;628-637.
26. Bernard B.F., Krenning E.P., Breeman W.A., Rolleman E.J., Bakker W.H., Visser T.J., Mäcke H.R., de Jong M. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 38:1997;1929-1933.
27. Kimura N, Schindler M, Kasai N, Kimura I, Immunohistochemical localization of somatostatin receptor type 2a in rat and human tissues. Endocr J. 48:2001;95-102.
28. Balster D.A., O'Dorisio M.S., Summers M.A., Turman M.A. Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol. 280:2001;457-465.
29. Turman M.A., Apple A.C. Human proximal tubular epithelial cells express somatostatin regulation by growth factors and Camp. Am J Physiol. 274:(Renal Physiol 43):1998;1095-1101.
30. Dileepan K.N., Wagle S.R. Somatostatin a metabolite regulator. Life Sci. 37:1985;2335-2343.
31. Decristoforo C., Mather S.J. Technetium-99m somatostatin analogues effect of labelling methods and peptide sequence. Eur J Nucl Med. 26:1999;869-876.
32. Boudin H., Sarret P., Mazella J., Schonbrunn A., Beaudet A. Somatostatin-induced regulation of sst2a receptor expression and cell surface availability in central neurons role of receptor internalization. J Neurosci. 20:2000;5932-5939.
33. Lukinius A., Öhrvall U., Westlin J.E., Öberg K., Janson E.T. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. Acta Oncol. 38:1999;383-387.
34. Nouel D., Gaudriault G., Houle M., Reisine T., Vincent J.P., Mazella J., Beaudet A. Differential internalization of somatostatin in cos-7 cells transfected with sst1 and sst2 receptor subtypes a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology. 138:1997;296-306.